Overexpression of p27(Kip1) inhibits the growth of both normal and transformed human mammary epithelial cells

Cancer Research

Volumn 58, Issue 15, 1998, Pages 3448-3454

  Sgambato, Alessandro ^a   Zhang, Yu Jing ^b   Ciaparrone, Marco ^a   Soh, Jae Won ^b   Cittadini, Achille ^a   Santella, Regina M ^b   Weinstein, I Bernard ^b,c  

^a CATHOLIC UNIVERSITY   (Italy)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c NewYork Presbyterian Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P27; CELL CYCLE PROTEIN; COMPLEMENTARY DNA; CYCLIN DEPENDENT KINASE INHIBITOR 1B; MICROTUBULE ASSOCIATED PROTEIN; TUMOR SUPPRESSOR PROTEIN;

ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CELL GROWTH; CELL STRAIN MCF 7; CELL TRANSFORMATION; CONTROLLED STUDY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MALIGNANT TRANSFORMATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; BIOSYNTHESIS; BREAST; BREAST TUMOR; CELL ADHESION; CELL CULTURE; CELL CYCLE; CELL DIVISION; CELL LINE; CYTOLOGY; EPITHELIUM CELL; GENETIC TRANSFECTION; GENETICS; METABOLISM; PATHOLOGY; PHYSIOLOGY;

BREAST; BREAST NEOPLASMS; CELL ADHESION; CELL CYCLE; CELL CYCLE PROTEINS; CELL DIVISION; CELL LINE; CELL TRANSFORMATION, NEOPLASTIC; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DNA, COMPLEMENTARY; EPITHELIAL CELLS; HUMANS; MICROTUBULE-ASSOCIATED PROTEINS; TRANSFECTION; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEINS;

EID: 0032129273     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Draetta, G. F. Mammalian G1 cyclins. Curr. Opin. Cell Biol., 6: 842-846, 1994.
2. Sherr, C. J. D-type cyclins. Trends Biochem. Sci., 20: 187-190, 1995.
3. Elledge, S. J., and Harper, J. W. Cdk inhibitors: on the threshold of checkpoints and development. Curr. Opin. Cell Biol., 6: 847-852, 1994.
4. Sherr, C. J., and Roberts, J. M. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev., 9: 1149-1163, 1995.
5. Serrano, M., Hannon, G. J., and Beach, D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature (Lond.), 366: 704-707, 1993.
6. INK4B is a potential effector of TGF-β-induced cell cycle arrest. Nature (Lond.), 371: 257-261, 1994.
7. INK4/MTS2-related CDK6 inhibitor, correlates with wild-type Rb function. Genes Dev., 8: 2939-2952, 1994.
8. Hirai, H., Roussel, M. F., Kato, J., Ashmun, R. A., and Sherr, C. J. Novel INK4 proteins, p19 and p18, are specific inhibitors of the cyclin D-dependent kinase CDK4 and CDK6. Mol. Cell. Biol., 15: 2672-2681, 1995.
9. Harper, J. W., Adami, G., Wei, N., Keyomarsi, K., and Elledge, S. J. The p21kd Cdk interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell, 75: 805-816, 1993.
10. Toyoshima, H., and Hunter, T. p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell, 78: 67-74, 1994.
11. Kip1, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution. Genes Dev., 9: 639-649, 1995.
12. Hunter, T., and Pines, J. Cyclins and cancer II: cyclin D and CDK inhibitors come of age. Cell, 79: 573-582, 1994.
13. Kamb, A., Gruis, N. A., Weaver-Feldhaus, J., Liu, Q., Harshman, K., Tavtigian, S. V., Stockert, E., Day, R. S. I., Johnson, B. E., and Skolnick, M. H. A cell cycle regulator potentially involved in genesis of many tumor types. Science (Washington DC), 264: 436-440, 1994.
14. Merlo, A., Herman, J. G., Mao, L., Lee, D. J., Gabrielson, E., Burger, P. C., Baylin, S. B., and Sidransky, D. 5′ CpG island methylation is associated with transcriptional silencing of the tumor suppressor p16/CDKN2/MTS1 in human cancers. Nat. Med., 1: 686-692, 1995.
15. Serrano, M., Lee, H-W., Chin, L., Cordon-Cardo, C., Beach, D., and De Pinho, R. A. Role of the INK4a locus in tumor suppression and cell mortality. Cell, 85: 27-37, 1996.
16. Kip1, to regions involved in human cancer. Cancer Res., 55: 1199-1205, 1995.
17. Kip1 gene to 12p13 and its analysis in leukemias. Cancer Res., 55: 1206-1210, 1995.
18. Kip1: chromosomal mapping to 12p12-12p13.1 and absence of mutations in human tumors. Cancer Res., 55: 1211-1214, 1995.
19. Shiohara, M., El-Deiry, W. S., Wada, M., Nakamaki, T., Takeuchi, S., Yang, R., Chen, D-L., Vogelstein, B., and Keoffler, H. P. Absence of WAF1 mutations in a variety of human malignancies. Blood, 84: 3781-3784, 1994.
20. Brugarolas, J., Chandrasekaran, C., Gordon, J. I., Beach, D., Jacks, T., and Hannon, G. J. Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature (Lond.), 377: 552-557, 1995.
21. 1 checkpoint control. Cell, 82: 675-684, 1995.
22. Kip1-deficient mice. Cell, 85: 733-744, 1996.
23. Kip1. Cell, 85: 721-732, 1996.
24. Kip1 display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell, 85: 707-720, 1996.
25. Kip1. Cancer Res., 56: 1389-1399, 1996.
26. Kip1 expression. Cell Growth Differ., 8: 393-405, 1997.
27. Kip1, inhibits growth, and enhances apoptosis. Cell Growth Differ., 7: 699-710, 1996.
28. Gillett, C., Fantl, V., Smith, R., Fisher, C., Bartek, J., Dickson, C., Barnes, D., and Peters, G. Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. Cancer Res., 54: 1812-1817, 1994.
29. Keyomarsi, K., O'Leary, N., Molnar, G., Lees, E., Fingert, H. J., and Pardee, A. B. Cyclin E, a potential prognostic marker for breast cancer. Cancer Res., 54: 380-385, 1994.
30. Keyomarsi, K., Conte, D., Jr., Toyofuku, W., and Fox, M. P. Deregulation of cyclin E in breast cancer. Oncogene, 11: 941-950, 1995.
31. Kip1 in human breast cancers. Clin. Cancer Res., 3: 1879-1887, 1997.
32. Kip1 in multistage colorectal carcinogenesis. Cancer Res., 58: 114-122, 1998.
33. Kip1 and degree of malignancy in human breast and colorectal cancers. Proc. Natl. Acad. Sci. USA, 94: 6380-6385, 1997.
34. Soule, H. D., Maloney, T. M., Wolman, S. R. W. D., Peterson, J., Brenz, R., McGrath, C. M., Russo, J., Pauly, R. J., Jones, R. F., and Brooks, S. C. Isolation and characterization of a spontaneously immortalized human breast epithelial cell line, MCF-10. Cancer Res., 50: 6075-6086, 1990.
35. Han, E. K., Sgambato, A., Jiang, W., Zhang, Y., Santella, R. M., Doki, Y., Cacace, A. M., Schieren, I., and Weinstein, I. B. Stable overexpression of cyclin D1 in a human mammary epithelial cell line prolongs the S-phase and inhibits growth. Oncogene, 10: 953-962, 1995.
36. Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell, 78: 59-66, 1994.
37. Kip1 in primary breast carcinomas. Hum. Genet., 97: 91-94, 1996.
38. Kip1 mutations found in breast cancer. Cancer Res., 56: 2400-2404, 1996.
39. Clurman, B. E., Sheaff, R. J., Thress, K., Groudine, M., and Robertys, J. M. Turnover of cyclin E by the ubiquitin-proteasome pathway is regulated by cdk2 binding and cyclin phosphorylation. Genes Dev., 10: 1979-1990, 1996.
40. Kip1. Genes Dev., 11: 1464-1478, 1997.
41. Kip1 protein in human esophageal cancer cell lines that overexpress cyclin D1. Carcinogenesis (Lond.), 18: 1139-1148, 1997.
42. Kip1 is associated with the p16MTS1 gene status in human esophageal carcinoma cell lines. J Exp. Ther. Oncol., 1: 7-12, 1996.
43. Meijer, L. Chemical inhibitors of cyclin-dependent kinases. Trends Cell Biol., 6: 393-397, 1996.
44. Kip1 induces cell cycle arrest and loss of cyclin-Cdk activity in human breast cancer cells. Oncogene, 14: 2283-2289, 1997.
45. Kip1. J. Clin. Invest., 97: 1983-1988, 1996.
46. 1 in mammalian cells: inhibition of cyclin E-dependent kinase by TGF-β. Science (Washington DC), 260: 536-539, 1993.
47. Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-β and contact inhibition to cell cycle arrest. Genes Dev., 8: 9-22, 1994.
48. Kip1 in γ interferon-mediated growth arrest of mammary epithelial cells and related defects in mammary carcinoma cells. Oncogene, 14: 2111-2122, 1997.
49. Kip1 in a human gastric carcinoma cell line. Cell Growth Differ., 8: 47-52, 1997.
50. Kip1) of cyclin-dependent kinase 4 activation. Cell, 79: 487-496, 1994.
51. Kip1 cyclin-dependent kinase inhibitor prevented by rapamycin. Nature (Lond.), 372: 570-573, 1994.